Industry Overview - The diabetes patient population is expected to reach 853 million globally by 2050, creating significant demand for diagnosis and treatment due to the chronic nature of the disease [3] - The Continuous Glucose Monitoring (CGM) market is projected to grow from $5.7 billion in 2020 to $36.5 billion by 2030, driven by technological advancements [3] - The insulin pump market, particularly patch-style devices, is rapidly developing, with the closed-loop artificial pancreas expected to become mainstream by 2026 [3] Company Profile - Weitai Medical is the only company in China with both a commercially available patch-style insulin pump and a real-time, no-calibration CGM, with the artificial pancreas expected to receive approval by 2026 [4] - The company has established itself as a leader in the domestic market, with superior product performance and a strong distribution network, achieving significant sales milestones such as being the top seller on Tmall for CGM products during the 2025 Double Eleven shopping festival [4] - Weitai Medical's overseas revenue surged to 121 million yuan in the first half of 2025, marking a 218% increase, indicating strong growth potential in international markets [5] Financial Outlook - The company is expected to turn a profit, with operating cash flow turning positive in the first half of 2025, and a projected net profit of 31 million yuan in 2025, increasing to 154 million yuan by 2027 [5] - The current market valuation is significantly undervalued, with a price-to-sales ratio of around 2 times for 2025 revenue, compared to historical valuations of comparable companies [5] - The target market capitalization is set at 5.8 billion HKD, with a target share price of 13.7 HKD, reflecting a strong buy recommendation [5]
【华创医药】微泰医疗-B（02235.HK）深度研究报告：国产糖尿病管理领先者，面向全球迈入发展新阶段